Drugs / rSh28GST
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01512277 | Sep 1998 → Mar 1999 | urinary schistosomiasis | University Hospital, Lille | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00870649 | Feb 2009 → Jun 2012 | urinary schistosomiasis | French National Institute of Health and Medical Research | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rSh28GST | “of Sh (rSh28GST) designated as Bilhvax” PMID 30532268 ↗ Dec 2018 |
| Known as | Bilhvax | “of Sh (rSh28GST) designated as Bilhvax” PMID 30532268 ↗ Dec 2018 |
| Modality | Vaccine | “a vaccine candidate against human urinary schistosomiasis” NCT01512277 ↗ |
| Route | Subcutaneous | “three subcutaneous injections of either rSh28GST/Alhydrogel” PMID 30532268 ↗ Dec 2018 |